Covaxin set for clinical trials on children aged between 2 and 18 years
Covaxin set for clinical trials on children aged between 2 and 18 years
The trial will take place in 525 subjects at various sites, including AIIMS Delhi, AIIMS Patna and Meditrina Institute of Medical Sciences, Nagpur.
Share
Updated: May 12, 2021, 12:06 PM IST
In a breakthrough, an expert panel recommended Bharat Biotech was on Tuesday to send its COVID-19 vaccine ‘Covaxin’ for phase II and phase III clinical trials on children between the ages of two and 18 years. The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur, officials said.
India s second COVID-19 wave flattening but won t wane away before July, says Shahid Jameel
Shahid Jameel noted that it is a little too early to say if the Covid wave has peaked
PTI | May 12, 2021 | Updated 13:49 IST
India s second COVID-19 wave seems to have flattened but the climb down will be a more prolonged, long drawn-out process than the first and will possibly run till July, eminent virologist Shahid Jameel said here on Tuesday.
Though the new variants of the virus may partly be responsible for the explosion in the number of cases, there is no indication the mutant versions are more lethal, added the director of the Trivedi School of Biosciences, Ashoka University, amid mounting worries about what is fuelling the second wave in India.
URL copied Image Source : PTI
Bharat Biotech s Covaxin recommended by expert panel for phase 2/3 trials on 2-18 year-olds
Bharat Biotech s COVID-19 vaccine Covaxin was on Tuesday recommended by an expert panel for phase II/III clinical trial on those aged between two to 18 years, official sources said. The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.
The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) on Tuesday deliberated upon Hyderabad-based Bharat Biotech s application seeking permission to conduct phase II/III clinical trials to evaluate the safety, reactogenicity and immunogenicity of Covaxin jabs in children aged 2 to 18 years.
1938 Children play on an empty street during COVID-induced lockdown in Lucknow on May 1, 2021. PTI/file
New Delhi, May 11
Bharat Biotech s COVID-19 vaccine Covaxin was on Tuesday recommended by an expert panel for phase II/III clinical trial on those aged between two to 18 years, official sources said.
The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.
The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) on Tuesday deliberated upon Hyderabad-based Bharat Biotech s application seeking permission to conduct phase II/III clinical trials to evaluate the safety, reactogenicity and immunogenicity of Covaxin jabs in children aged 2 to 18 years.